Bayer Expands Capacity for Biologicals
Bayer plans to further expand its position in the market for biological crop protection products and has invested some16 million euros in new capacity for research, development and production at its Wismar site.
“As a global, innovation-driven Life Science company, we have not only set ourselves ambitious growth targets,” says Mathias Kremer, head of strategy and portfolio management at the Crop Science Division, to approximately 100 guests at the inauguration ceremony on Oct. 6. “The capacity expansion at the Wismar site is also an important step in offering farmers around the world new solutions for modern, sustainable agriculture. The use of biologicals is becoming increasingly important in this context.”
“The integrated site at Wismar will play a major part in our growth plans,” adds Daniel Karsch, managing director of Bayer CropScience Biologics GmbH. “We have created ideal conditions in Wismar to ensure that our scientists and experts can work together successfully in the fermentation and production of natural fungi.”
Wismar is part of the company’s global R&D network and an important production site for biologicals. Bayer employs a total of some 45 people at the site.
Bayer has concentrated its research and development activities on natural fungi in Wismar. At the disposal of the company’s researchers is an approximately 1,600 m2, two-story building complex comprising laboratories, technical centers and offices.
The newly built production facility meets all product quality and safety standards. With an area of more than 4,000 m2, the facility offers enough space for optimal production conditions. As a result, Bayer is well equipped for the future and can react flexibly to new market conditions.